DiaMedica Therapeutics Reports Full-Year 2025 Financial Results, Advances Preeclampsia and Acute Ischemic Stroke Programs, and Anticipates Cash Runway Through 2H 2027.

DiaMedica Therapeutics reported FY25 financial results and provided business highlights. The company received regulatory approval from Health Canada for a Phase 2 DM199 study in early-onset preeclampsia. The DM199 Preeclampsia Phase 2 IST is enrolling, with completion expected in 1H 2026. The ReMEDy2 Phase 2/3 AIS trial is approaching 70% of required enrollment, with an interim analysis planned in 2H 2026. DiaMedica has $60 million in cash, cash equivalents, and investments, anticipating a runway through 2H 2027.